{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:28:30Z","timestamp":1792214910703,"version":"4.4.0"},"reference-count":65,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2025,6,17]]},"DOI":"10.18632\/oncotarget.28741","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:46:17Z","timestamp":1750171577000},"page":"481-494","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing enfortumab vedotin plus pembrolizumab therapy"],"prefix":"10.18632","volume":"16","author":[{"given":"Elias Antoine","family":"Karam","sequence":"first","affiliation":[{"name":"Departements de M\u00e9decine Oncologique, Gustave Roussy F-94805, Villejuif, France"},{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaghi C\u00e9sar","family":"C\u00e9line","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon"},{"name":"These authors contributed equally to this work"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Prince","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Attieh","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampig Raphael","family":"Kourie","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Nemer","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, Screening, and Prevention of Bladder Cancer","volume":"5","author":"Lotan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2","unstructured":"Cancer Today. https:\/\/gco.iarc.who.int\/today\/."},{"key":"3","unstructured":"Key Statistics for Bladder Cancer. https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html."},{"key":"4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00428-014-1596-4","article-title":"FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer","volume":"46","author":"van der Kwast","year":"2014","journal-title":"Virchows Arch"},{"key":"5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12885-021-08078-y","article-title":"RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer","volume":"2","author":"Brugarolas","year":"2021","journal-title":"BMC Cancer"},{"key":"6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/pgs-2023-0027","article-title":"Implication ofin bladder cancer","volume":"2","author":"Kourie","year":"2023","journal-title":"Pharmacogenomics"},{"key":"7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-1-4939-7234-0_23","article-title":"Targeting the PI3K\/AKT\/mTOR Pathway in Bladder Cancer","volume":"165","author":"Nawroth","year":"2018","journal-title":"Methods Mol Biol"},{"key":"8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00345-020-03498-0","article-title":"PD-L1 testing in urothelial bladder cancer: essentials of clinical practice","volume":"3","author":"Allory","year":"2021","journal-title":"World J Urol"},{"key":"9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/iju5.12678","article-title":"Successful treatment with enfortumab-vedotin of metastatic signet ring cell cancer expressing nectin-4 and originating from the bladder","volume":"7","author":"Yasui","year":"2023","journal-title":"IJU Case Rep"},{"key":"10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3892\/ol.2023.14114","article-title":"Immunohistochemical expression of TROP-2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer","volume":"2","author":"Schlack","year":"2023","journal-title":"Oncol Lett"},{"key":"11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.ju.0000162039.38023.5f","article-title":"Update on chemotherapy for advanced bladder cancer","volume":"17","author":"Small","year":"2005","journal-title":"J Urol"},{"key":"12","unstructured":"Cancer. Net. 2012. Bladder Cancer - Statistics. https:\/\/www.cancer.net\/cancer-types\/bladder-cancer\/statistics."},{"key":"13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.hoc.2014.10.013","article-title":"Diagnosis and staging of bladder cancer","volume":"2","author":"Trinh","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"14","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.path.2022.07.004","article-title":"Molecular Taxonomy and Immune Checkpoint Therapy in Bladder Cancer","volume":"1","author":"Czerniak","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"15","doi-asserted-by":"publisher","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of Luminal and Basal Phenotypes in Bladder Cancer","volume":"1","author":"Wei","year":"2020","journal-title":"Sci Rep"},{"key":"16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.32074\/1591-951X-838","article-title":"News in the classification of WHO 2022 bladder tumors","volume":"11","author":"Netto","year":"2022","journal-title":"Pathologica"},{"key":"17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.3390\/jpm13050756","article-title":"Precision Medicine in Bladder Cancer: Present Challenges and Future Directions","volume":"1","author":"Cheng","year":"2023","journal-title":"J Pers Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"S96","DOI":"10.1038\/modpathol.2009.26","article-title":"Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications","volume":"2","author":"Amin","year":"2009","journal-title":"Mod Pathol"},{"key":"19","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.path.2022.07.003","article-title":"Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes","volume":"1","author":"Al-Ahmadie","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"20","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/molecules29081896","article-title":"Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma","volume":"2","author":"Tester","year":"2024","journal-title":"Molecules"},{"key":"21","unstructured":"Frontiers | Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma. https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2022.1069356\/full#B35."},{"key":"22","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"THOR Cohort 1 Investigators. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma","volume":"38","author":"Kean","year":"2023","journal-title":"N Engl J Med"},{"key":"23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.urolonc.2016.10.004","article-title":"A review of the PD-1\/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment","volume":"3","author":"Zang","year":"2017","journal-title":"Urol Oncol"},{"key":"24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.6004\/jadpro.2020.11.4.8","article-title":"Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin","volume":"1","author":"Hanna","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.17305\/bjbms.2021.6100","article-title":"Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers","volume":"2","author":"Gatalica","year":"2022","journal-title":"Bosn J Basic Med Sci"},{"key":"26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"1","author":"Lowe","year":"1992","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","article-title":"Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924","volume":"1","author":"Collette","year":"2001","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"4","author":"Collette","year":"2006","journal-title":"Eur J Cancer"},{"key":"29","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"1","author":"Wersall","year":"2000","journal-title":"J Clin Oncol"},{"key":"30","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"2","author":"Arning","year":"2005","journal-title":"J Clin Oncol"},{"key":"31","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"2","author":"Bellmunt","year":"2011","journal-title":"J Clin Oncol"},{"key":"32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"3","author":"Sylvester","year":"2012","journal-title":"J Clin Oncol"},{"key":"33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma","volume":"8","author":"Rouanne","year":"2022","journal-title":"Eur Urol"},{"key":"34","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"1","author":"Keefe","year":"2017","journal-title":"Lancet Oncol"},{"key":"35","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma","volume":"38","author":"\u00dcr\u00fcn","year":"2023","journal-title":"N Engl J Med"},{"key":"36","article-title":"FDA approves pembrolizumab for advanced endometrial carcinoma","author":"Food and Drug Administration","year":"2022","journal-title":"FDA"},{"key":"37","doi-asserted-by":"publisher","first-page":"102050","DOI":"10.1016\/j.esmoop.2023.102050","article-title":"Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice","volume":"8","author":"Sternberg","year":"2023","journal-title":"ESMO Open"},{"key":"38","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"38","author":"Tsuchiya","year":"2020","journal-title":"N Engl J Med"},{"key":"39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"2","author":"Tagawa","year":"2022","journal-title":"Lancet Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"38","author":"Tagawa","year":"2019","journal-title":"N Engl J Med"},{"key":"41","doi-asserted-by":"publisher","first-page":"1756287220980192","DOI":"10.1177\/1756287220980192","article-title":"Enfortumab Vedotin in urothelial cancer","volume":"1","author":"Sridhar","year":"2020","journal-title":"Ther Adv Urol"},{"key":"42","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience","volume":"2","author":"Brannon","year":"2023","journal-title":"Clin Cancer Res"},{"key":"43","first-page":"4516","article-title":"Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"4","author":"Petrylak","year":"2022","journal-title":"JCO"},{"key":"44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1200\/JCO.2021.39.6_suppl.393","article-title":"Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma","volume":"3","author":"Petrylak","year":"2021","journal-title":"JCO"},{"key":"45","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"3","author":"Kyriakopoulos","year":"2021","journal-title":"J Clin Oncol"},{"key":"46","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1200\/JCO.2021.39.15_suppl.453","article-title":"Pembrolizumab (pembro) versus investigator\u2019s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial","volume":"3","author":"Culine","year":"2021","journal-title":"JCO"},{"key":"47","doi-asserted-by":"publisher","first-page":"v366","DOI":"10.1093\/annonc\/mdz249.018","article-title":"Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator\u2019s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)","volume":"3","author":"Quinn","year":"2019","journal-title":"Ann Oncol"},{"key":"48","article-title":"FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer","author":"Food and Drug Administration","year":"2023","journal-title":"FDA"},{"key":"49","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1097\/MS9.0000000000002601","article-title":"Milestone achieved: FDA approves nivolumab in combination with cisplatin and gemcitabine for metastatic urothelial carcinoma","volume":"8","author":"Akilimali","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"50","doi-asserted-by":"publisher","first-page":"636","DOI":"10.4143\/crt.2022.343","article-title":"Neoadjuvant Nivolumab Plus Gemcitabine\/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder","volume":"5","author":"Park","year":"2023","journal-title":"Cancer Res Treat"},{"key":"51","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity inExpression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin","volume":"2","author":"Black","year":"2021","journal-title":"Clin Cancer Res"},{"key":"52","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance","volume":"2","author":"Schwamborn","year":"2023","journal-title":"Clin Cancer Res"},{"key":"53","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.annonc.2023.08.016","article-title":"EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma","volume":"3","author":"Petrylak","year":"2023","journal-title":"Ann Oncol"},{"key":"54","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-21-3089","article-title":"Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials","volume":"2","author":"Bajorin","year":"2022","journal-title":"Clin Cancer Res"},{"key":"55","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer","volume":"3","author":"Frenkl","year":"2020","journal-title":"J Clin Oncol"},{"key":"56","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"39","author":"Li","year":"2024","journal-title":"N Engl J Med"},{"key":"57","unstructured":"Enfortumab Vedotin and Pembrolizumab \u2014 A New Perspective on Urothelial Cancer | New England Journal of Medicine. https:\/\/www.nejm.org\/doi\/10.1056\/NEJMe2400311."},{"key":"58","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"3","author":"Gillessen","year":"2024","journal-title":"Ann Oncol"},{"key":"59","unstructured":"Oncology Nursing News. Newer Urothelial Cancer Drugs Are Effective But Pricey. 2023. https:\/\/www.oncnursingnews.com\/view\/newer-urothelial-cancer-drugs-are-effective-but-pricey."},{"key":"60","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"2","author":"Heath","year":"2021","journal-title":"Lancet Oncol"},{"key":"61","unstructured":"Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer | Cellular & Molecular Biology Letters | Full Text. https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-023-00442-z."},{"key":"62","unstructured":"Utilization of Circulating Tumor DNA as a Biomarker of Response in a Case of Metastatic Urothelial Carcinoma Treated with Efortumab Vedotin and Pembrolizumab | Published in International Journal of Cancer Care and Delivery. https:\/\/journal.binayfoundation.org\/article\/90317-utilization-of-circulating-tumor-dna-as-a-biomarker-of-response-in-a-case-of-metastatic-urothelial-carcinoma-treated-with-efortumab-vedotin-and-pembro."},{"key":"63","article-title":"A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15\/EV-304)","author":"Dohme","year":"2024","journal-title":"clinicaltrials.gov"},{"key":"64","article-title":"A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (MK-3475-905\/KEYNOTE-905\/EV-303)","author":"Dohme","year":"2025","journal-title":"clinicaltrials.gov"},{"key":"65","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/jco.22.01792","article-title":"Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After \u22652 Years of Follow-Up","volume":"4","author":"Huang","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T14:46:21Z","timestamp":1750171581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,6,17]]}},"alternative-id":["28741"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28741","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}